{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:43:27Z","timestamp":1791362607257,"version":"4.3.1"},"reference-count":64,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Tremendous data have been accumulated in the effort to understand chemoresistance of triple negative breast cancer (TNBC). However, modifications in cancer cells surviving combined and sequential treatment still remain poorly described. In order to mimic clinical neoadjuvant treatment, we first treated MDA-MB-231 and SUM159-PT TNBC cell lines with epirubicin and cyclophosphamide for 2 days, and then with paclitaxel for another 2 days. After 4 days of recovery, persistent cells surviving the treatment were characterized at both cellular and molecular level. Persistent cells exhibited increased growth and were more invasive in vitro and in zebrafish model. Persistent cells were enriched for vimentinhigh sub-population, vimentin knockdown using siRNA approach decreased the invasive and sphere forming capacities as well as Akt phosphorylation in persistent cells, indicating that vimentin is involved in chemotherapeutic treatment-induced enhancement of TNBC aggressiveness. Interestingly, ectopic vimentin overexpression in native cells increased cell invasion and sphere formation as well as Akt phosphorylation. Furthermore, vimentin overexpression alone rendered the native cells resistant to the drugs, while vimentin knockdown rendered them more sensitive to the drugs. Together, our data suggest that vimentin could be considered as a new targetable player in the ever-elusive status of drug resistance and recurrence of TNBC.<\/jats:p>","DOI":"10.3390\/cells10061504","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T11:00:33Z","timestamp":1623754833000},"page":"1504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment"],"prefix":"10.3390","volume":"10","author":[{"given":"Marie","family":"Winter","sequence":"first","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7978","authenticated-orcid":false,"given":"Samuel","family":"Meignan","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"},{"name":"Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1550","authenticated-orcid":false,"given":"Pamela","family":"V\u00f6lkel","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-4796","authenticated-orcid":false,"given":"Pierre-Olivier","family":"Angrand","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Chopin","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"},{"name":"UFR Sciences, University of Picardie Jules Verne, 33 rue Saint Leu, F-80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Bidan","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-2118","authenticated-orcid":false,"given":"Robert-Alain","family":"Toillon","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adriaenssens","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-2069","authenticated-orcid":false,"given":"Chann","family":"Lagadec","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-6358","authenticated-orcid":false,"given":"Xuefen","family":"Le Bourhis","sequence":"additional","affiliation":[{"name":"UMR9020\u2014U1277-CANTHER\u2014Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"ref_1","first-page":"4429","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Siddahart, S., and Sharma, D. (2018). Racial disparity and triple-negative breast cancer in African-american women: A multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers, 10.","DOI":"10.3390\/cancers10120514"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.3747\/co.25.3954","article-title":"Advances in the systemic treatment of triple-negative breast cancer","volume":"25","author":"Lebert","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","article-title":"Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells","volume":"7","author":"Mukherjee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41419-017-0087-3","article-title":"ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1158\/0008-5472.CAN-14-0067","article-title":"Paclitaxel therapy promotes breast cancer metastasis in TLR4-dependent manner","volume":"74","author":"Hall","year":"2014","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of chemotherapy resistance in triple-negative breast cancer-How we can rise to the challenge. Cells, 8.","DOI":"10.3390\/cells8090957"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OTT.S67673","article-title":"Triple-negative breast cancer: New perspectives for targeted therapies","volume":"8","author":"Tomao","year":"2015","journal-title":"OncoTarget Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/pgs-2017-0117","article-title":"Triple-negative breast cancer and the potential for targeted therapy","volume":"18","author":"Jhan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000151705","article-title":"Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer","volume":"54","author":"Ichinose","year":"2008","journal-title":"Chemotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","article-title":"Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer","volume":"11","author":"Mielke","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2008.12.073","article-title":"Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness","volume":"379","author":"Tran","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/1440-1681.12960","article-title":"Low doses of paclitaxel repress breast cancer invasion through DJ-1\/KLF17 signalling pathway","volume":"45","author":"Ismail","year":"2018","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/febs.13767","article-title":"Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model","volume":"283","author":"Li","year":"2016","journal-title":"FEBS J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4048\/jbc.2019.22.e22","article-title":"Doxorubicin promotes migration and invasion of breast cancer cells through the upregulation of the RhoA\/MLC pathway","volume":"22","author":"Liu","year":"2019","journal-title":"J. Breast Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.canlet.2019.02.019","article-title":"ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2","volume":"449","author":"Corbet","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/onc.2009.61","article-title":"TrkA overexpression enhances growth and metastasis of breast cancer cells","volume":"28","author":"Lagadec","year":"2009","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1038\/s41598-019-44452-4","article-title":"Encapsulation of TRPM8 agonist, WS12, in lipid nanocapsules potentiates PC3 prostate cancer cell migration inhibition through channel activation","volume":"9","author":"Grolez","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pmic.201800454","article-title":"Transcriptomic analysis of breast cancer stem cells and development of a pALDH1A1:mNeptune reporter system for live tracking","volume":"19","author":"Bidan","year":"2019","journal-title":"Proteomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9807","DOI":"10.18632\/oncotarget.3227","article-title":"NGF-induced TrkA\/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib","volume":"6","author":"Aubert","year":"2015","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nmeth.1664","article-title":"A photoswitchable orange-to-far-red fluorescent protein, PSmOrange","volume":"8","author":"Subach","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semcancer.2018.11.006","article-title":"Therapy resistance mediated by cancer stem cells","volume":"53","author":"Steinbichler","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.03.036","article-title":"Breast cancer stem cells: Multiple capacities in tumor metastasis","volume":"349","author":"Geng","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_25","first-page":"2723","article-title":"Resistance to taxanes in triple-negative breast cancer associates with the dynamics of CD49f+ tumor-initiating population","volume":"19","author":"Palafox","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/ncomms7139","article-title":"Temporally sequenced anticancer drugs overcome adaptative resistance by targeting a vulnerable chemotherapy-induced phenotypic transition","volume":"6","author":"Goldman","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Danielson, F., Peterson, M.K., Caldeira Ara\u00fajo, H., Lautenschl\u00e4ger, F., and Gad, A.K.B. (2018). Vimentin diversity in health and disease. Cells, 7.","DOI":"10.3390\/cells7100147"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.18632\/oncotarget.3862","article-title":"Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_29","first-page":"187772","article-title":"Low adherent cancer cell subpopulation are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells","volume":"6","author":"Entrena","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct function of AKT isoforms in breast cancer: A comprehensive review","volume":"17","author":"Hinz","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/onc.2010.421","article-title":"Vimentin is a novel AKT1 target mediating motility and invasion","volume":"30","author":"Zhu","year":"2011","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","article-title":"The fate of chemoresistance in triple negative breast cancer (TNBC)","volume":"3","author":"Gubbins","year":"2015","journal-title":"BBA Clin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/cas.13888","article-title":"Role of inhibitor of yes-associated protein 1 in triple negative breast cancer with taxol-based chemoresistance","volume":"110","author":"Li","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13058-014-0512-9","article-title":"BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers","volume":"17","author":"Blanchard","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2932","DOI":"10.1038\/cddis.2017.319","article-title":"An autocrine inflammatory forward-feeback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells","volume":"8","author":"Jia","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/bjc.2013.534","article-title":"Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistance triple-negative breast cancer cells","volume":"109","author":"Liu","year":"2013","journal-title":"Brit. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12282-012-0357-y","article-title":"Prognostic significance of NANOG and KFL4 for breast cancer","volume":"21","author":"Nagata","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/onc.2013.209","article-title":"The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis","volume":"33","author":"Lu","year":"2014","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ctm.ctm_69_16","article-title":"Stemness-related markers in cancer","volume":"3","author":"Zhao","year":"2017","journal-title":"Cancer Transl. Med."},{"key":"ref_40","first-page":"901","article-title":"High expression level of \u03b16 integrin in human breast carcinoma is correlated with reduced survival","volume":"55","author":"Friedrichs","year":"1995","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4048\/jbc.2015.18.3.242","article-title":"The presence of EpCAM\u2212\/CD49f+ cells in breast cancer is associated with a poor clinical outcome","volume":"18","author":"Ye","year":"2015","journal-title":"J. Breast Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Brooks, D., Schwab, L., Krutilina, R., Park, D., Sethuraman, A., Hoogewijs, D., Sch\u00f6rg, A., Gotwald, L., Fan, M., and Wenger, R. (2016). ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol. Cancer, 15.","DOI":"10.1186\/s12943-016-0510-x"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Strouhalova, K., P\u0159echov\u00e1, M., Gandalovi\u010dov\u00e1, A., Br\u00e1bek, J., Gregor, M., and Rosel, D. (2020). Vimentin intermediate filaments as potential target for cancer treatment. Cancers, 12.","DOI":"10.3390\/cancers12010184"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1242\/dev.154229","article-title":"Epithelial vimentin plays a functional role in mammary gland development","volume":"144","author":"Peuhu","year":"2017","journal-title":"Development"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00432-013-1376-6","article-title":"Vimentin as a poor prognostic factor for triple-negative breast cancer","volume":"139","author":"Yamashita","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105514","DOI":"10.1016\/j.jsbmb.2019.105514","article-title":"6 \u03b1-Hydroxy-4[14], 10[15]-guainadien-8\u03b2, 12-olide induced cell cycle arrest via modulation of EMT and Wnt\/\u03b2-catenin pathway in HER-2 positive breast cancer cells","volume":"197","author":"Javir","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-018-0988-8","article-title":"Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors","volume":"37","author":"Su","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1083\/jcb.201607045","article-title":"Regulation of microtubule-associated motors drives intermediate filament network polarization","volume":"216","author":"Leduc","year":"2017","journal-title":"J. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1096\/fj.09-151639","article-title":"Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition","volume":"24","author":"Mendez","year":"2010","journal-title":"FASEB J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2015.05.008","article-title":"Bidirectional interplay between vimentin intermediate filaments and contractile actin stress fibers","volume":"11","author":"Jiu","year":"2015","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1242\/jcs.196881","article-title":"Vimentin intermediate filaments control actin stress fiber assembly through GEF-H1 and Rhoa","volume":"130","author":"Jiu","year":"2017","journal-title":"J. Cell Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/sj.emboj.7600847","article-title":"PKC\u03b5-mediated phosphorylation of vimentin controls integrin recycling and motility","volume":"24","author":"Ivaska","year":"2005","journal-title":"EMBO J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-14-2842","article-title":"Vimentin-ERK signaling uncouples slug gene regulatory function","volume":"75","author":"Virtakoivu","year":"2015","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/onc.2010.509","article-title":"Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer","volume":"30","author":"Vuoriluoto","year":"2011","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/onc.2016.305","article-title":"Silencing vimentin expression decreases pulmonary metastases in pre-diabetic mouse model of mammary tumor progression","volume":"36","author":"Zelenko","year":"2017","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10697","DOI":"10.18632\/aging.102485","article-title":"MAP2K4 interacts with vimentin to activate the PI3K\/AKT pathway and promotes breast cancer pathogenesis","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Matte, B.F., Kumar, A., Placone, J.K., Zanella, V.G., Martins, M.D., Engler, A.J., and Lamers, M.L. (2019). Matrix stiffness mechanically conditions EMT and migratory behavior of oral squamous cell carcinoma. J. Cell Sci., 132.","DOI":"10.1242\/jcs.224360"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E4574","DOI":"10.1073\/pnas.1703057114","article-title":"Selective regulation of Notch ligands during angiogenesis is mediated by vimentin","volume":"114","author":"Antfolk","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Van Engeland, N., Rodriguez, F., Rivero-M\u00fcller, A., Ristori, T., Duran, C., Stassen, O., Antfolk, D., Driessen, R., Ruohonen, S., and Ruohonen, S. (2019). Vimentin regulates Notch signaling strength and arterial remodeling in response to hemodynamic stress. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-48218-w"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-017-3112-z","article-title":"Vimentin is a crucial target for anti-metastasis therapy of nasopharyngeal carcinoma","volume":"438","author":"Wang","year":"2018","journal-title":"Mol. Cell Biochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1096\/fj.201700663R","article-title":"An image-based small-molecules screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells","volume":"32","author":"Trogden","year":"2018","journal-title":"FASEB J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-08-1510","article-title":"Withaferin A causes FOXO3a- and Bim-Dependent apoptosis and inhibits growth of human breast cancer cells in vivo","volume":"15","author":"Stan","year":"2008","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mc.22110","article-title":"Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors","volume":"54","author":"Lee","year":"2015","journal-title":"Mol. Carcinog."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2007.04.010","article-title":"The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin","volume":"14","author":"Hamza","year":"2007","journal-title":"Chem. Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:14:23Z","timestamp":1760163263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cells10061504"],"URL":"https:\/\/doi.org\/10.3390\/cells10061504","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}